Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration
News Jan 12, 2006
Roche and Xencor entered into an initial collaboration in January 2005, in which Roche applies Xencor's XmAb Fc domains with the aim of enhancing the therapeutic efficacy of an antibody against a cancer target.
"We are very pleased to continue working with Roche to apply our XmAb proprietary engineered Fc domains to enhance the efficacy of Roche's proprietary antibodies," said Bassil Dahiyat, Ph.D., President and CEO of Xencor.
Under the original collaboration, Xencor received technology access and license fees, and is eligible to receive additional license fees, milestones and royalties in the event that Roche advances candidates into development. Xencor will receive additional fees for the extension.
Broadly Acting Antibodies Found in Blood of Ebola SurvivorsNews
Scientists have discovered a set of powerful, broadly neutralizing antibodies in the blood of Ebola survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness.READ MORE
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE